DOBMEIER ERIC 4

What Happened

• Eric Dobmeier, a director of Jade Biosciences (JBIO), was granted a derivative award on June 9, 2026 representing the right to purchase 34,843 shares. The Form 4 reports the transaction as an award/derivative (code A) and shows $0.00 for the reported price — this reflects a grant of rights/options rather than a cash purchase or sale. No immediate cash changed hands or shares were sold.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-11 (appears timely under Form 4 rules).
• Reported instrument: derivative award (option/right) for 34,843 shares; price shown on the filing: $0.00.
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: the award "represents a right to purchase shares" and vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting, subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or immediate sale noted in the filing.

Context

• This is a typical director equity award granting the right to buy shares in the future; it is not an immediate purchase or sale and does not necessarily reflect a short-term trading signal. The filing does not state the exercise/strike price or whether the options are incentive or non-qualified; those details may be in the company’s equity plan or a separate grant agreement.